Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions
COVID-19Pneumonia
Interventions
DRUG

Heparin

"Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement."

Trial Locations (60)

10467

Montefiore-Einstein Center for Heart and Vascular Care, New York

30308

Emory University Hospital Midtown, Atlanta

37232

Vanderbilt University Medical Center, Nashville

48128

Henry Ford University, Dearborn

48336

Beaumont Hospital, Royal Oak

55905

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

63104

Saint Louis University School of Medicine/Saint Louis Veterans Affairs Medical Center, St Louis

70121

Ochsner Clinic, Jefferson

04102

Maine Medical Center, Portland

08103

Cooper University Health Care, Camden

07601

Hackensack University Medical Center, Hackensack

07039

Saint Barnabas Medical Center, Livingston

Unknown

Hospital Unimed do Cariri, Juazeiro do Norte

Santa Casa de Misericordia de Itabuna, Itabuna

Instituto Goiano de Oncologia e Hematologia - INGOH, Goiânia

Centro de Pesquisas Clínicas Humap - UFMS, Campo Grande

Clinica de Campo Grande S/A, Campo Grande

Unimed Campo Grande, Campo Grande

Hospital Felício Rocho, Belo Horizonte

Hospital das Clinicas da UFPR, Curitiba

Pontifícia Universidade Católica do Paraná, Curitiba

Parana Medical Research Center, Maringá

Hospital Agamenon Magalhaes, Recife

Hospital Universitario Pedro Ernesto, Rio de Janeiro

Hospital Sao Vicente de Paulo, Passo Fundo

Hospital de Clinicas de Porto Alegre, Porto Alegre

Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre

Instituto de Medicina Vascular, Porto Alegre

AngioCor Blumenau, Blumenau

Instituto de Cardiologia de Santa Catarina, São José

Instituto de Pesquisa Clínica de Campinas, Campinas

Praxis Pesquisa Medica, Santo André

Casa de Saúde Santa Marcelina, São Paulo

Instituto de Molestias Cardio Vasculares de Tatui, Tatuí

Santa Casa de Votuporanga, Votuporanga

Hospital 9 de Julho, São Paulo

Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo

Instituto de Infectologia Emilio Ribas, São Paulo

Instituto do Coração do Estado de São Paulo, São Paulo

Sociedade Beneficente Israelita Hospital Albert Einstein, São Paulo

Victoria General Hospital, Victoria

Grace General Hospital, Winnipeg

St. Boniface General Hospital, Winnipeg

Hamilton Health Sciences, Hamilton

St. Joseph's Healthcare Hamilton, Hamilton

Hôpital Montfort, Ottawa

The Ottawa Hospital, Ottawa

Centre Hospitalier de l'université de Montréal (CHUM), Montreal

Jewish General Hospital, Montreal

CHU de Quebec-University Laval, Québec

Institut universitaire de cardiologie et de pneumologie de Québec (CRIUCPQ), Québec

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

Regina General Hospital, Regina

Hospital de Infectolog´ñia Centro Médico Nacional La Raza, Azcapotzalco

Hospital General Regional 1 Carlos MacGregor Sánchez Navarro, Benito Juárez

Hospital General regional 2 El Marqués, Querétaro

R3A 1R9

Health Sciences Center Winnipeg, Winnipeg

M5G2C4

University Health Network, Toronto

H4A3J1

McGill University Health Centre, Montreal

All Listed Sponsors
collaborator

University Health Network, Toronto

OTHER

lead

University of Manitoba

OTHER

NCT04372589 - Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | Biotech Hunter | Biotech Hunter